Therapeutic manipulation of natural killer (NK)T cells in autoimmunity: Are we close to reality?

Clinical and Experimental Immunology

Volumn 171, Issue 1, 2013, Pages 8-19

  Simoni, Y ^a   Diana, J ^a   Ghazarian, L ^a   Beaudoin, L ^a   Lehuen, A ^a  

^a INSERM   (France)

Author keywords

Autoimmunity; CD1; MAIT; NKT cells; Therapy

Indexed keywords

ALPHA GALACTOSYLCERAMIDE;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL MANIPULATION; CELL TYPE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; GRAVES DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MUCOSAL ASSOCIATED INVARIANT T CELL; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; AUTOIMMUNITY; CLINICAL TRIALS, PHASE I AS TOPIC; DIABETES MELLITUS, TYPE 1; FEMALE; GALACTOSYLCERAMIDES; HUMANS; LIVER CIRRHOSIS, BILIARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MULTIPLE SCLEROSIS; NATURAL KILLER T-CELLS; PSORIASIS;

EID: 84870424721     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04625.x     Document Type: Article

References (136)

1. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4:231-7.
2. Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol 2005; 5:387-99.
3. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010; 10:501-13.
4. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11:197-206.
5. O'Reilly V, Zeng SG, Bricard G etal. Distinct and overlapping effector functions of expanded human CD4, CD8alpha and CD4CD8alpha invariant natural killer T Cells. PLoS ONE 2011; 6:e28648.
6. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195:625-36.
7. Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002; 100:11-6.
8. McNab FW, Pellicci DG, Field K etal. Peripheral NK1.1 NKT cells are mature and functionally distinct from their thymic counterparts. J Immunol 2007; 179:6630-7.
9. Michel ML, Keller AC, Paget C etal. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007; 204:995-1001.
10. Coquet JM, Chakravarti S, Kyparissoudis K etal. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci USA 2008; 105:11287-92.
11. Terashima A, Watarai H, Inoue S etal. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med 2008; 205:2727-33.
12. Thedrez A, de Lalla C, Allain S etal. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood 2007; 110:251-8.
13. Uldrich AP, Patel O, Cameron G etal. A semi-invariant Valpha10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol 2011; 12:616-23.
14. Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci USA 2010; 107:10984-9.
15. Chang DH, Deng H, Matthews P etal. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood 2008; 112:1308-16.
16. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199:947-57.
17. Giabbai B, Sidobre S, Crispin MD etal. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation. J Immunol 2005; 175:977-84.
18. Van Rhijn I, Young DC, Im JS etal. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci USA 2004; 101:13578-83.
19. Huber S, Sartini D, Exley M. Role of CD1d in coxsackievirus B3-induced myocarditis. J Immunol 2003; 170:3147-53.
20. Treiner E, Lantz O. CD1d- and MR1-restricted invariant T cells: of mice and men. Curr Opin Immunol 2006; 18:519-26.
21. Dusseaux M, Martin E, Serriari N etal. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011; 117:1250-9.
22. Shimamura M, Huang YY, Okamoto N etal. Modulation of Valpha19 NKT cell immune responses by alpha-mannosyl ceramide derivatives consisting of a series of modified sphingosines. Eur J Immunol 2007; 37:1836-44.
23. Huang S, Gilfillan S, Kim S etal. MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells. J Exp Med 2008; 205:1201-11.
24. Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G. Presentation of the same glycolipid by different CD1 molecules. J Exp Med 2002; 195:1013-21.
25. Young MH, Gapin L. Group 1 CD1-restricted T cells take center stage. Eur J Immunol 2011; Feb 9. doi: 10.1002/eji.201041408.
26. de Lalla C, Lepore M, Piccolo FM etal. High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells. Eur J Immunol 2011; 41:602-10.
27. de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. CD1a-autoreactive T cells are a normal component of the human alphabeta T cell repertoire. Nat Immunol 2010; 11:1102-9.
28. Cui Y, Kang L, Cui L, He W. Human gammadelta T cell recognition of lipid A is predominately presented by CD1b or CD1c on dendritic cells. Biol Direct 2009; 4:47.
29. Kasmar AG, van Rhijn I, Cheng TY etal. CD1b tetramers bind alphabeta T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. J Exp Med 2011; 208:1741-7.
30. Mattner J, Savage PB, Leung P etal. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008; 3:304-15.
31. van der Vliet HJ, von Blomberg BM, Nishi N etal. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001; 100:144-8.
32. Novak J, Lehuen A. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine 2011; 53:263-70.
33. Oh SJ, Chung DH. Invariant NKT cells producing IL-4 or IL-10, but not IFN-gamma, inhibit the Th1 response in experimental autoimmune encephalomyelitis, whereas none of these cells inhibits the Th17 response. J Immunol 2011; 186:6815-21.
34. Mars LT, Laloux V, Goude K etal. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002; 168:6007-11.
35. Mars LT, Gautron AS, Novak J etal. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol 2008; 181:2321-9.
36. Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003; 15:279-88.
37. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164:4375-81.
38. Croxford JL, Miyake S, Huang YY, Shimamura M, Yamamura T. Invariant V(alpha)19i T cells regulate autoimmune inflammation. Nat Immunol 2006; 7:987-94.
39. Illes Z, Shimamura M, Newcombe J, Oka N, Yamamura T. Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 2004; 16:223-30.
40. Miyazaki Y, Miyake S, Chiba A, Lantz O, Yamamura T. Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis. Int Immunol 2011; 23:529-35.
41. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G. Self glycolipids as T-cell autoantigens. Eur J Immunol 1999; 29:1667-75.
42. Podbielska M, Hogan EL. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult Scler 2009; 15:1011-29.
43. Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993; 177:155-64.
44. Mieza MA, Itoh T, Cui JQ etal. Selective reduction of V alpha 14+ NKT cells associated with disease development in autoimmune-prone mice. J Immunol 1996; 156:4035-40.
45. Forestier C, Molano A, Im JS etal. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black × New Zealand White) F1 mice. J Immunol 2005; 175:763-70.
46. Takahashi T, Strober S. Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur J Immunol 2008; 38:156-65.
47. Yang JQ, Wen X, Liu H etal. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum 2007; 56:1219-33.
48. Yang JQ, Chun T, Liu H etal. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004; 34:1723-32.
49. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med 2010; 207:943-52.
50. Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012; 36:477-90.
51. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001; 44:1127-38.
52. Sieling PA, Porcelli SA, Duong BT etal. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 2000; 165:5338-44.
53. Miellot A, Zhu R, Diem S, Boissier MC, Herbelin A, Bessis N. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 2005; 35:3704-13.
54. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum 2005; 52:1941-8.
55. Kim HY, Kim S, Chung DH. FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation. J Clin Invest 2006; 116:2484-92.
56. Miellot-Gafsou A, Biton J, Bourgeois E, Herbelin A, Boissier MC, Bessis N. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Immunology 2010; 130:296-306.
57. Kim HY, Kim HJ, Min HS etal. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta1 production. J Exp Med 2005; 201:41-7.
58. Kojo S, Tsutsumi A, Goto D, Sumida T. Low expression levels of soluble CD1d gene in patients with rheumatoid arthritis. J Rheumatol 2003; 30:2524-8.
59. Yanagihara Y, Shiozawa K, Takai M, Kyogoku M, Shiozawa S. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999; 118:131-6.
60. Parietti V, Chifflot H, Sibilia J, Muller S, Monneaux F. Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Clin Immunol 2010; 134:331-9.
61. Linsen L, Thewissen M, Baeten K etal. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R493-502.
62. Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J Clin Invest 2011; 121:249-64.
63. Chiba A, Tajima R, Tomi C, Miyazaki Y, Yamamura T, Miyake S. Mucosal-associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis. Arthritis Rheum 2011; 64:153-61.
64. Hammond KJ, Pellicci DG, Poulton LD etal. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001; 167:1164-73.
65. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26:2989-98.
66. Lehuen A, Lantz O, Beaudoin L etal. Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188:1831-9.
67. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998; 187:1047-56.
68. Shi FD, Flodstrom M, Balasa B etal. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA 2001; 98:6777-82.
69. Laloux V, Beaudoin L, Jeske D, Carnaud C, Lehuen A. NKT cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J Immunol 2001; 166:3749-56.
70. Forestier C, Takaki T, Molano A etal. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J Immunol 2007; 178:1415-25.
71. Hong S, Wilson MT, Serizawa I etal. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7:1052-6.
72. Sharif S, Arreaza GA, Zucker P etal. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7:1057-62.
73. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002; 17:725-36.
74. Chen YG, Choisy-Rossi CM, Holl TM etal. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005; 174:1196-204.
75. Naumov YN, Bahjat KS, Gausling R etal. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 2001; 98:13838-43.
76. Simoni Y, Gautron AS, Beaudoin L etal. NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes. Eur J Immunol 2011; 41:3574-85.
77. Zekavat G, Mozaffari R, Arias VJ etal. A novel CD93 polymorphism in non-obese diabetic (NOD) and NZB/W F1 mice is linked to a CD4+ iNKT cell deficient state. Immunogenetics 2010; 62:397-407.
78. Wilson SB, Kent SC, Patton KT etal. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391:177-81.
79. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110:793-800.
80. Kukreja A, Cost G, Marker J etal. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109:131-40.
81. Oikawa Y, Shimada A, Yamada S etal. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care 2002; 25:1818-23.
82. Berzins SP, Kyparissoudis K, Pellicci DG etal. Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies. Immunol Cell Biol 2004; 82:247-52.
83. Kent SC, Chen Y, Clemmings SM etal. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol 2005; 175:4458-64.
84. Duarte N, Stenstrom M, Campino S etal. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol 2004; 173:3112-8.
85. Kadri N, Korpos E, Gupta S etal. CD4+ type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol 2012; 188:3138-49.
86. Shimamura M, Huang YY, Goji H, Endo S, Migishima R, Yokoyama M. Regulation of immunological disorders by invariant Valpha19-Jalpha33 TCR-bearing cells. Immunobiology 2011; 216:374-8.
87. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 1999; 135:546-52.
88. Gilhar A, Ullmann Y, Kerner H etal. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002; 119:384-91.
89. Zhao Y, Fishelevich R, Petrali JP etal. Activation of keratinocyte protein kinase C zeta in psoriasis plaques. J Invest Dermatol 2008; 128:2190-7.
90. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22:361-403.
91. Major AS, Wilson MT, McCaleb JL etal. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24:2351-7.
92. Nakai Y, Iwabuchi K, Fujii S etal. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104:2051-9.
93. Tupin E, Nicoletti A, Elhage R etal. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004; 199:417-22.
94. To K, Agrotis A, Besra G, Bobik A, Toh BH. NKT cell subsets mediate differential proatherogenic effects in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2009; 29:671-7.
95. Bobryshev YV, Lord RS. Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J Histochem Cytochem 2005; 53:781-5.
96. Chan WL, Pejnovic N, Hamilton H etal. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ Res 2005; 96:675-83.
97. Kyriakakis E, Cavallari M, Andert J etal. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur J Immunol 2010; 40:3268-79.
98. Melian A, Geng YJ, Sukhova GK, Libby P, Porcelli SA. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am J Pathol 1999; 155:775-86.
99. Zeissig S, Blumberg RS. Primary immunodeficiency associated with defects in CD1 and CD1-restricted T cells. Ann NY Acad Sci 2012; 1250:14-24.
100. Kitamura H, Iwakabe K, Yahata T etal. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189:1121-8.
101. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198:267-79.
102. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004; 199:1607-18.
103. Kojo S, Seino K, Harada M etal. Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J Immunol 2005; 175:3648-55.
104. Singh AK, Wilson MT, Hong S etal. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194:1801-11.
105. Jahng AW, Maricic I, Pedersen B etal. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194:1789-99.
106. Van Kaer L. Alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005; 5:31-42.
107. Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S. Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. Arthritis Rheum 2007; 56:1836-45.
108. Mizuno M, Masumura M, Tomi C etal. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004; 23:293-300.
109. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003; 171:4439-46.
110. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003; 112:1211-22.
111. Bilenki L, Yang J, Fan Y, Wang S, Yang X. Natural killer T cells contribute to airway eosinophilic inflammation induced by ragweed through enhanced IL-4 and eotaxin production. Eur J Immunol 2004; 34:345-54.
112. Umetsu DT, Dekruyff RH. Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma. J Allergy Clin Immunol 2010; 125:975-9.
113. Lisbonne M, Diem S, Keller A etal. Cutting edge: invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol 2003; 171:1637-41.
114. Thomas SY, Chyung YH, Luster AD. Natural killer T cells are not the predominant T cell in asthma and likely modulate, not cause, asthma. J Allergy Clin Immunol 2010; 125:980-4.
115. Goff RD, Gao Y, Mattner J etal. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004; 126:13602-3.
116. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413:531-4.
117. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum 2004; 50:305-13.
118. Ueno Y, Tanaka S, Sumii M etal. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of valpha14 natural killer T cells in mice. Inflamm Bowel Dis 2005; 11:35-41.
119. Ly D, Tohn R, Rubin B etal. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes. Clin Exp Immunol 2010; 160:185-98.
120. Blumenfeld HJ, Tohn R, Haeryfar SM, Liu Y, Savage PB, Delovitch TL. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol 2011; 166:121-33.
121. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007; 117:2302-12.
122. Motohashi S, Ishikawa A, Ishikawa E etal. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006; 12:6079-86.
123. Gumperz JE, Roy C, Makowska A etal. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000; 12:211-21.
124. Brennan PJ, Tatituri RV, Brigl M etal. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol 2011; 12:1202-11.
125. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204:208-31.
126. Gigli G, Caielli S, Cutuli D, Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 2007; 122:409-17.
127. Yue SC, Shaulov A, Wang R, Balk SP, Exley MA. CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc Natl Acad Sci USA 2005; 102:11811-6.
128. Montoya CJ, Pollard D, Martinson J etal. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 2007; 122:1-14.
129. Novak J, Griseri T, Beaudoin L, Lehuen A. Regulation of type 1 diabetes by NKT cells. Int Rev Immunol 2007; 26:49-72.
130. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11:131-42.
131. Exley MA, Tahir SM, Cheng O etal. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol 2001; 167:5531-4.
132. Treiner E, Duban L, Moura IC, Hansen T, Gilfillan S, Lantz O. Mucosal-associated invariant T (MAIT) cells: an evolutionarily conserved T cell subset. Microbes Infect 2005; 7:552-9.
133. Felio K, Nguyen H, Dascher CC etal. CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. J Exp Med 2009; 206:2497-509.
134. Gapin L. iNKT cell autoreactivity: what is 'self' and how is it recognized? Nat Rev Immunol 2010; 10:272-7.
135. Hegde S, Fox L, Wang X, Gumperz JE. Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology 2010; 130:471-83.
136. Wekerle H, Flugel A, Fugger L, Schett G, Serreze D. Autoimmunity's next top models. Nat Med 2012; 18:66-70.